Novo Nordisk A/S
—- Market cap
- —
- Debt
- —
- Cash
- −$3.97B
USD conversion input: 1 DKK = 0.150160 USD. FX date unavailable.
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: NVO stock price vs ABBV: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ABBV's multiple
Needs ABBV P/E.
Implied fair value · at NVO's multiple
Needs NVO P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
USD conversion input: 1 DKK = 0.150160 USD. FX date unavailable.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
NOVO NORDISK A/S · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
AbbVie Inc. · implied price per share
Bear
$74.44
Base
$92.88
Bull
$117.70
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe NVO's low valuation multiples reflect temporary market mispricing rather than a real deterioration in business quality, then consider the name because it trades below ABBV on every listed valuation metric and near the low end of its historical band; otherwise, the very weak F-Score argues for caution.
NVO trades at 12.7x P/E versus ABBV at 92.3x, and also at lower P/S, EV/EBITDA, and EV/Revenue multiples, indicating a broad valuation discount. However, the modeled implied price of $331.50 sits far above the current price of $45.59, while ABBV-implied range and DCF range are both well above the stock, creating a mixed signal between relative cheapness and model-based upside.
Supporting Metrics